Long-term treatment with darifenacin for overactive bladder: Results of a 2-year, open-label extension study

BJU International

Volumn 98, Issue 5, 2006, Pages 1025-1032

  Haab, François ^a   Corcos, Jacques ^b   Siami, Paul ^c   Glavind, Karin ^d   Dwyer, Peter ^e   Steel, Michael ^f   Kawakami, Fernando ^f   Lheritier, Karine ^f   Steers, William D ^g  

^a HÔPITAL TENON   (France)

^b MCGILL UNIVERSITY   (Canada)

^c Welborn Clinic   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e MERCY HOSPITAL FOR WOMEN   (Australia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bowel habits; Clinical trial; Darifenacin; Long term treatment; Overactive bladder

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COUGHING; DEFECATION HABIT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; OVERACTIVE BLADDER; PAIN; PARESTHESIA; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SINUSITIS; SOMNOLENCE; TACHYCARDIA; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PYRROLIDINES; TREATMENT OUTCOME; URINARY INCONTINENCE; XEROSTOMIA;

EID: 33749545229     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06439.x     Document Type: Article

References (18)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
3. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
4. Andersson KE. Pharmacological treatment of urinary incontinence. In Abrams P, Khoury S, Wein A eds, Incontinence, 2nd International Consultation on Incontinence. Plymouth: Plymbridge Distributors Ltd, 2002: 480-511
5. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19: 299-306
6. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
7. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20: 470-5
8. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95: 993-1001
9. 3 selective receptor antagonist. Eur Urol 2005; 48: 471-7
10. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8
11. 3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005; 96: 1055-62
12. 3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005; 45: 1038-47
13. 3-selective receptor antagonist. BJU Int 2005; 95: 580-6; erratum 2005; 95: 1385-6
14. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
15. 3 receptor selectivity. Eur Urol 2002; 1 (Suppl.): 23-8
16. Abrams P, Malone-Lee J, Jacquetin B et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551-60
17. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9
18. 3 receptor subtype. Neurourol Urodyn 2002; 21: A445